MAPK3 and neoplasm: In tumor specimens acquired after 2 wk of treatment, EHT1864 greatly reduced levels of P-ERK1/2, P-AKT, P-p70S6K, and P-Histone H3S10 (marker of mitosis) (Figure 6B).